Takeda Announces FY2026 First-Half Results Highlighting Launch Momentum and Pipeline Milestones
ORZEYFULTM approved in the U.S., Japan and China for narcolepsy type 1 (NT1), MIMRYLOTM launched in the U.S. for erythrocytosis in polycythemia vera (PV) Zasocitinib advances to U.S. Food & Drug Administration (FDA) Priority Review and European Medicines Agency (EMA) review Late-stage pipeline continues to advance FY2026 full-year outlook upgraded to reflect foreign exchange (FX) […]
We haven't written up this one. Financial Post has the full story — the link below goes straight to it.
